Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1Phase 1/2 1Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Neoplasms 3Neoplasm Metastasis 2Carcinoma, Hepatocellular 2Solid Tumors 1Pyloric Stenosis, Hypertrophic 1Ovarian Neoplasms 1Liver Neoplasms 1Gastrointestinal Neoplasms 1Colorectal Neoplasms 1

Interventions

Fluorouracil 71pembrolizumab 62Bevacizumab 60Oxaliplatin 59Cetuximab 59Leucovorin 56Irinotecan 55Capecitabine 31Nivolumab 23Gemcitabine 18Cisplatin 18IFL protocol 17Folfox protocol 17Cyclophosphamide 16Carboplatin 15atezolizumab 14Specimen Handling 14Paclitaxel 14Magnetic Resonance Spectroscopy 14Biopsy 14trifluridine tipiracil drug combination 12Pemetrexed 10spartalizumab 9regorafenib 9fludarabine 9Panitumumab 9130-nm albumin-bound paclitaxel 9trametinib 8durvalumab 8dehydroftorafur 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Colorectal Neoplasms × brivanib × Clear all
NCT00207051 2011-01-25

BMS-582664 in Combination With Erbitux in Patients With Advanced Gastrointestinal Malignancies

Bristol-Myers Squibb

Phase 1 Completed
62 enrolled
Gastrointestinal

Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡